首页> 美国卫生研究院文献>other >Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch
【2h】

Enhanced Immune Responses Conferring Cross-Protection by Skin Vaccination With a Tri-Component Influenza Vaccine Using a Microneedle Patch

机译:通过使用三针型流感疫苗使用微针贴片接种皮肤疫苗进行交叉保护可增强免疫反应

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Skin vaccination using biodegradable microneedle patch (MNP) technology in vaccine delivery is a promising strategy showing significant advantages over conventional flu shots. In this study, we developed an MNP encapsulating a 4M2e-tFliC fusion protein and two types of whole inactivated influenza virus vaccines (H1N1 and H3N2) as a universal vaccine candidate. We demonstrated that mice receiving this tri-component influenza vaccine via MNP acquired improved IgG1 antibody responses with more balanced IgG1/IgG2a antibody responses and enhanced cellular immune responses, including increased populations of IL-4 and IFN-γ producing cells and higher frequencies of antigen-specific plasma cells compared with intramuscular injection. In addition, stronger germinal center reactions, increased numbers of Langerin-positive migratory dendritic cells, and increased cytokine secretion were observed in the skin-draining lymph nodes after immunization with the tri-component influenza MNP vaccine. The MNP-immunized group also possessed enhanced protection against a heterologous reassortant A/Shanghai/2013 H7N9 (rSH) influenza virus infection. Furthermore, the sera collected from 4M2e-tFliC MNP-immunized mice were demonstrated to have antiviral efficacy against reassortant A/Vietnam/1203/2004 H5N1 (rVet) and A/Shanghai/2013 H7N9 (rSH) virus challenges. The immunological advantages of skin vaccination with this tri-component MNP vaccine could offer a promising approach to develop an easily applicable and broadly protective universal influenza vaccine.
机译:在疫苗递送中使用可生物降解的微针贴片(MNP)技术进行皮肤疫苗接种是一种有前途的策略,与传统的流感疫苗相比,它具有明显的优势。在这项研究中,我们开发了一种封装4M2e-tFliC融合蛋白的MNP和两种全灭活流感病毒疫苗(H1N1和H3N2)作为通用疫苗候选物。我们证明了通过MNP接受这种三组分流感疫苗的小鼠获得了改善的IgG1抗体反应和更平衡的IgG1 / IgG2a抗体反应,并增强了细胞免疫反应,包括增加的IL-4和IFN-γ产生细胞的数量以及更高的抗原频率肌内注射比较特异性血浆细胞。此外,在用三组分流感MNP疫苗免疫后,在引流皮肤的淋巴结中观察到了更强的生发中心反应,朗格林阳性迁移树突细胞数量增加和细胞因子分泌增加。 MNP免疫组还具有针对异源重配株A / Shanghai / 2013 H7N9(rSH)流感病毒感染的增强保护。此外,从4M2e-tFliC MNP免疫小鼠收集的血清被证明具有抗重组A / Vietnam / 1203/2004 H5N1(rVet)和A / Shanghai / 2013 H7N9(rSH)病毒攻击的抗病毒功效。用这种三组分MNP疫苗进行皮肤疫苗接种的免疫学优势可以为开发易于应用和广泛保护的通用流感疫苗提供有前途的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号